Biogen to bulk up rare disease treatments with $7 billion Reata acquisition

Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments. The Alzheimer’s treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year. Plano, Texas-based Reata focuses…#biogen #reatapharmaceuticals #reata #plano #fda #freidreich #techfidera #tysabri #spinraza #leqembi
Source: Reuters: Health - Category: Consumer Health News Source Type: news